Clinical Trials Logo

Advanced Non-squamous NSCLC clinical trials

View clinical trials related to Advanced Non-squamous NSCLC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03778853 Not yet recruiting - Clinical trials for Advanced Non-squamous NSCLC

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Start date: January 2019
Phase: Phase 4
Study type: Interventional

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor celltebiz related kinase -c-Kit kinase. In the phase III study, Patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib (12mg, po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months.